Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients

Inclusion Criteria:

* Diagnosis of NF2 by National Institutes of Health (NIH) criteria
* Age ≥ 15 years
* Progressive VS growth during the previous 12 months. Evidence of disease progression defined by progressive VS during the previous 12 months (\>20% increase in volume) in subjects who are at elevated risk for surgical complications (eg, deafness, lower cranial nerve injury, facial weakness) or who refuse surgery
* Adequate bone marrow, liver and renal function.
* For women of childbearing potential, no pregnancy or breast-feeding
* Willingness and ability to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.
* Willingness to provide informed consent

Exclusion Criteria:

* Inability to tolerate periodic MRI scans or gadolinium contrast.
* Inability to tolerate periodic audiologic testing or to understand a language with established scoring for word recognition testing.
* Inability to adequately perform volumetric measurement of at least 1 target lesionNote: Patients with cochlear or auditory brainstem implants may participate if a target lesion can be accurately assessed.
* Radiation therapy for the target lesion in the 60 months preceding inclusion in the study.
* Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug.
* Immunization with attenuated live vaccines within one week of study entry or during study period.
* Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
* Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.
* Patients who have any severe and/or uncontrolled medical conditions.
* Patients with a known hypersensitivity to everolimus or other types of rapamycin or to its excipients.
* Patients unwilling to or unable to comply with the protocol